

PRELIMINARY PROGRAM

www.eurothrombosis-summit2009.no

THURSDAY 08.10.09

Satellite /Special Symposium

- 1750-1800** **Welcome**
H.Arnese, Oslo (N)
- 1800-2000** **A survey on anti-thrombotics in CAD**
Chairs: I.Seljeftot, Oslo (N) / F.Andreotti, Rome (IT)
- 1800-1830 Antiplatelets
R.De Caterina, Chieti (IT)
- 1830-1900 Anticoagulants
F.Verheugt, Amsterdam (NL)
- 1900-1930 Where to go?
L.Wallentin, Uppsala (S)
- 1930-2000 Between bench and bedside; Clinical research with anti-thrombotics
H.Arnese, Oslo (N)
- 2000** **Get together party**

FRIDAY 09.10.09

Scientific Sessions

- 0845 The ESC Working Group on Thrombosis: mission and activities
F.Andreotti, Rome (IT) (Chair of the WG18)
- 0900-1040** **Atherothrombosis in diabetes – special reference to AMI**
Chairs: H.Arnese, Oslo (N) / R.De Caterina, Chieti (IT)
- 0900-0920 Overview: Atherothrombosis in diabetes
T.Wascher, Vienna (A)
- 0920-0935 Diabetes and the heart. Therapeutic challenges
G.Ø.Andersen, Oslo (N)
- 0935-0950 The GLUMIK-study: Glucometabolic state in STEMI
E.C.Knudsen, Oslo (N)
- 0950-1005 Tissue factor and TFPI in diabetes with CAD
T.B.Opstad, Oslo (N)
- 1005-1025 The role of C-peptide in diabetes with CAD
N.Marx, Ulm (D)
- 1025-1040 Adipose tissue and CVD
T.Weiss, Oslo (N) / Vienna (A)
- 1040-1105** **Coffee break**

Parallell sessions

1105-1220 Arterial thrombosis during dual antiplatelet therapy

Chairs: R. Storey, Sheffield (UK) / H.Arnese, Oslo (N)

1105-1125 Mechanisms on thrombus formation.Updated view

L.Badimon, Barcelona (ES)

1125-1140 Mural thrombosis in AMI

S.Solheim, Oslo (N)

1140-1200 Late stent thrombosis

F.-J.Neumann, Bad Krozingen (DE)

1200-1215 Up-date on new stents

D.Gulba, Düren (D)

**1105-1220 Clinical problems in ACS;
In collaboration with WG Acute Coronary Care**

Chairs: S.D.Kristensen, Århus (DK) / Y.Hasin, Poriya (Israel)

1105-1125 Which drugs in the ambulance for ACS?

P.Goldstein, Lille (F)

1125-1145 Antithrombotic and antiplatelet therapy with primary PCI

D.Dudek, Krakow (P)

1145-1205 Challenges in the combination of antithrombotic and antiplatelet therapies in ACS

P.Clemmensen, Copenhagen (DK)

1205-1220 Net clinical benefit in ACS

M.Tubaro, Rome (IT)

1220-1230 Break

Lunch Symposium, sponsored by Daiichi Sankyo Europe GmbH and Eli Lilly and Company

1230-1400 Dual antiplatelet therapy in ACS/PCI patients: new developments

Chairs: K.Huber, Vienna (A) / H.Arnese, Oslo (N)

Thienopyridine pre-loading: benefits and risk

S.D.Kristensen, Århus (DK)

Antiplatelet response variability and clinical outcome: Implication for measuring platelet function in clinical routine

K.Huber, Vienna (A)

Prasugrel – Ready for clinical use

F.-J.Neumann, Bad Krozingen (DE)

1400-1510 Non-responsiveness to antiplatelets

Chairs: B.Rocca, Rome (IT) / S.D.Kristensen, Århus (DK)

1400-1420 Overview

M.Cattaneo, Milan (IT)

1420-1435 Aspirin non-responsiveness and Clopidogrel End-point Trial (ASCET): Status

A-Å.Petterson, Oslo (N)

1435-1450 Immature platelets and aspirin response in coronary artery disease

E.C.L.Grove, Århus (DK)

1450-1510 Clopidogrel non-responsiveness

J-P.Collet, Paris (F)

1510-1530 Coffee break

Parallel sessions

1530-1640

Atrial fibrillation – a prothrombotic state

Chairs: P.Smith, Oslo (N) / K.Huber, Vienna (A)

1530-1550

Pathophysiology and risk for stroke

G.Lip, Birmingham (UK)

1550-1605

PAI-1 prediction for relapse of AF post cardioversion

A.Tveit, Oslo (N)

1605-1620

Endothelial dysfunction in AF

I.Seljeflot, Oslo (N)

1620-1640

Anticoagulation in AF: Status

D.Atar, Oslo (N)

1530-1650

Clinical issues in thrombosis;

In collaboration with WG Acute Coronary Care

Chairs: P.Clemmensen, Copenhagen (DK) / M.Tubaro, Rome (IT)

1530-1550

Peri-operative management of antithrombotic therapy

Y.Hasin, Poriya (Israel)

1550-1610

Prophylaxis and treatment of venous thromboembolism

H.Bounameaux, Geneva (CH)

1610-1630

Ischaemic stroke: thrombolytic, antithrombotic and antiplatelet therapy

G.F.Gensini, Florence (IT)

1630-1650

Antiplatelet therapy and DES: critical issues

P.G.Steg, Paris (F)

1650-1720

Coffee break

Satellite Symposium

1720-1825

New antiplatelet drugs in CAD

Chairs: L.Hvilsted Rasmussen, Ålborg (DK) / A.Siegbahn, Uppsala (S)

1720-1740

Platelet physiology / activation: Overview with clinical relevance

K.Schrör, Düsseldorf (DE)

1740-1755

Cangrelor and Elinogrel – Drugs to overcome clopidogrel nonresponse?

S.D.Kristensen (DK)

1755-1810

Ticagrelor

L.Wallentin, Uppsala (S)

1810-1825

PAR-1 inhibitors

R.Storey, Sheffield (UK)

2000

Dinner party

SATURDAY 10.10.09

Scientific Sessions

0830-0935

Prehospital thrombolysis in STEMI

Chairs: S.Halvorsen, Oslo (N) / G.Lip, Birmingham (UK)

0830-0850

Prehospital thrombolysis and the current ECS STEMI guidelines

F. Van de Werf, Leuven (B)

0850-0905

NORDISTEMI: Status / results

E.Bøhmer, Lillehammer (N)

0905-0920

Other ongoing trials

G.Steg, Paris (F)

0920-0935

STEMI-“loop” – up-date

K.Huber, Vienna (A)

Bleeding in ACS session sponsored by The Medicines Company

0935-1040

Bleeding in ACS

Chairs: F.Andreotti, Rome (IT) / J.Eritsland, Oslo (N)

0935-0950

Up-date

G.Steg, Paris (F)

0950-1005

Definition of bleeding

R.Storey, Sheffield (UK)

1005-1020

MACE – including major bleeding

J.Morais, Leiria (P)

1020-1040

Hypercoagulability and bleeding

A.Siegbahn, Uppsala (S)

1040-1110

Coffee break

1110-1150

Oral anticoagulants in heart failure

Chairs: D.Atar, Oslo (N) / J.Morais, Leiria (P)

1110-1130

Antithrombotic treatment in HF; an overview

F.Andreotti, Rome (IT)

1130-1150

Ongoing clinical trials and future perspectives

J.G.B. Cleland, Hull (UK)

1150-1225

Up-date in stem-cell therapy in MI

Chairs: S.D.Kristensen, Århus (DK) / F.-J.Neumann, Bad Krozingen (DE)

1150-1210

Overview

J.F.Martin, London (UK)

1210-1225

Ongoing trials in MI

S.Solheim, Oslo (N)

1225-1315

“Pleiotropic effects of statins”

Chairs: T.Pedersen, Oslo (N) / I.Seljeflot, Oslo (N)

1225-1245

Focusing the link between lipids – coagulation – inflammation

J.Wojta, Vienna (A)

1245-1300

“Pleiotropic effects of statins” – existing?

No: *Anton FH. Stalenhoef, Nijmegen (NL)*

1300-1315 "Pleiotrophic effects of statins" – existing?
Yes: *C.Kluft, Sassenheim (NL)*

1315-1325 Break

Satellite /Special Symposium with lunch

1325-1440 New anticoagulants in CAD

Chairs: P. Smith, Oslo (N) / L.Badimon, Barcelona (ES)

1325-1340 Inhibition of blood coagulation: Overview with clinical relevance
H.Arnesen, Oslo (N)

1340-1355 FXa-inhibitors: ACS
K.Huber, Vienna (A)

1355-1410 FXa-inhibitors: Long-term
E.C.L. Grove, Århus (DK)

1410-1425 FIIa-inhibitors: ACS
L.Hvilsted-Rasmussen, Ålborg (DK)

1425-1440 FIIa-inhibitors: Long-term
F.Verheugt, Amsterdam (NL)

1440 Closing remarks

Organizing Committee:

H. Arnesen
I. Seljeflot
K. Huber
F. Andreotti
S. Dalby Kristensen
F.W.A. Verheugt
K.Fox
L. Badimon
R. De Caterina
D. Gulba
G. Steg